GeneticsCubed, a Green Rock Hemp Holdings company and part of Roche Enterprises, has achieved a huge milestone in its mission to be a scientific innovator and produce the highest performance seeds and clones in the hemp industry. The company recently submitted the first patent for a unique Cannabichromene (CBC) hemp cultivar, C2B. C2B is a high CBC hemp strain developed by selective breeding and high throughput screening of more than one million hemp plants.
Cannabichromene (CBC) is a rare, high-value cannabinoid, one of the most prominent in medical research. It is considered to have great potential for its antimicrobial, anti‐inflammatory, and analgesic characteristics. GeneticsCubed Research Scientist Thomas Azwell, Ph.D., believes CBC has great therapeutic potential. It is a minor cannabinoid, meaning it occurs in very small amounts. the C2B exceptional cultivar tests as high as 4 percent CBC, which is ten times the amount of commercially available ‘high’ CBC strains. Early research indicates CBC’s potential for treating acne, pain, and cancer by inhibiting inflammation. The market value of CBC is significantly higher than CBD, and it currently sells for more than 20 times the price.
This was a huge accomplishment for the GeneticsCubed team. The submission of this patent demonstrates its commitment to innovation and bringing scientific rigor to hemp cultivation. The Green Rock Hemp Holdings family of companies is dedicated to providing vertical solutions to the industrial hemp community.
In collaboration with the University of California-Berkeley, GeneticsCubed improves hemp with elevated levels of key cannabinoids. GeneticsCubed has also completed development of two other novel strains and will be submitting additional patent applications this year.